Novartis Pharmaceuticals and Alcon sponsor XOVA awards providing grant funding up to EUR 50,000 for non-profit programs in ophthalmology
365 Days of #MSLifeHacks featured on the Novartis website www.livinglikeyou.com
Ever heard of a life hack? Quite simply, life hacks are creative ways to make everyday tasks simpler. And when MS can lead to some pretty unique challenges, simplicity is golden. Over 365 days living Like You are sharing a new trick, shortcut, or clever way to live well, like you. There are over 30 life hacks listed to date so catch up on www.livinglikeyou.com!
Here’s one of our favourites – what’s yours?
Novartis present the Fighting Blindness Empower Award to Áine Lennon
The Fighting Blindness Empowerment Award, sponsored by Novartis, is a special honour given to those who help the charity Fighting Blindness with its mission to cure, support and empower people affected by sight loss. The award was presented to Áine Lennon from County Carlow. >>
First of its kind disease tracking and management resource launched for people with MS
Research shows that substantial numbers of people with MS currently do not record important symptom changes, despite the potential impact on their disease >>
Almost 400 people received a free AMD eye test from the Novartis mobile testing unit during AMD Awareness Week.
AMD (Age-Related Macular Degeneration) is the leading cause of blindness in Ireland and affects one in ten people over 50 with 7,000 new cases diagnosed each year. The AMD Awareness Campaign, which is supported by Fighting Blindness, NCBI: the National Sight Loss Organisation, the Irish College of Ophthalmologists, the Association of Optometrists Ireland and Novartis Ireland, highlights the importance of regular eye testing and the benefits of early diagnosis and treatment by encouraging more conversation about AMD >>
Novartis Supported the IICN Neuroscience Fellowship 2014
In the last 3 years Novartis Ireland in conjunction with the Irish Institute of Clinical Neuroscience have supported a one year fellowship grant in Clinical Neuroscience. The fellowship aims to provide outstanding neuroscientists, who should have the potential to become leaders in their chosen field, with the opportunity to conduct a significant research project and all applications are peer reviewed >>
Eye Health Campaign Highlights Leading Cause of Blindness in Diabetes
Celebrity chef, Andrew Rudd joined Diabetes Ireland, NCBI-the National Sight Loss Agency, Fighting Blindness, the Irish College of Ophthalmologists (ICO), the Association of Optometrists Ireland (AOI) and Novartis to support Eye Am What I Eat campaign. The campaign aimed to raise awareness of diabetic macular edema (DME) a form of diabetic retinopathy that can have a severe effect on vision, causing significant sight loss >>
New analyses show Novartis’ LCZ696 could change course of heart failure for patients
New data from PARADIGM-HF shows LCZ696 cut the incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus enalapril. >>
LCZ696 was recognised in Cleveland Clinic's Top 10 Medical Innovators for 2015
On Wednesday, October 29, the Cleveland Clinic announced its 9th annual list of Top 10 Medical Innovations that are likely to have a major impact on improving patient care in 2015. For the second year running Novartis’ Cardio Metabolic medicines made the list, with LCZ696 following serelaxin last year. >>
LCZ696 new heart failure medicine cuts cardiovascular deaths by 20%
Novartis’ new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial >>
World Urticaria Awareness Day October 1st 2014. Click here for more information.
Novartis to license Google "smart lens" technology
Novartis announced that its eye care division Alcon has entered into an agreement with a division of Google Inc. to in-license its “smart lens” technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google’s “smart lens” technology with the potential to transform eye care and further enhance Alcon’s pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals. >>
Novartis Ireland participates in International Clinical Trials Day
Novartis, in conjunction with ICORG (The All-Ireland Cooperative Oncology Research Group) and a number of pharmaceutical companies, mark International Clinical Trials Day. This day is celebrated worldwide to commemorate when James Lind began the first known trial comparing different treatments for scurvy, in 1747. >>